Evonik will manufacture its own GAA-product to replace CreAMINO® in portfolio
Evonik has made the strategic decision to launch its own guanidinoacetic acid-product (GAA) used to enhance energy metabolism in livestock production. The market launch is planned as soon as possible and became necessary after Trostberg-based, AlzChem Group AG terminated its supply agreement with Evonik as of 31.12.2018. The GAA product CreAMINO® currently distributed by Evonik is manufactured by AlzChem.
Evonik will continue to supply its customers until at least the end of 2018. The termination of the contract with AlzChem AG will open options for Evonik to further develop the use of GAA in animal nutrition and to supply the global market with its own GAA product.
"With our comprehensive animal nutrition expertise and our broad portfolio of feed additives, we are the perfect partner for the use of GAA in modern feeding concepts," says Dr Emmanuel Auer, Head of the Animal Nutrition Business Line at Evonik. "The product is an important element in healthy, efficient and sustainable animal nutrition. That's why we are working hard on a new solution and are pleased to take full ownership of GAA production."
Guanidinoacetic acid is an essential component for the organism in building creatine and it also serves as a key source of arginine. Creatine is vital for vertebrates as it contributes to ensuring that the muscle cells are supplied with energy. With the addition of GAA to animal feed, the feed conversion in livestock production can be improved.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,250 employees, and generated sales of around €4.5 billion in 2017.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.